---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-308469"
form_type: "8-K"
ticker: "TEM"
cik: "0001717115"
company_name: "Tempus AI, Inc."
filed_at: "2026-07-20T13:03:42+00:00"
generated_at: "2026-07-20T13:05:11.656099+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tempus AI to acquire Personalis for $1.5B, adding MRD technology to precision oncology platform

## Summary
- Total enterprise value of $1.5B net of Tempus' existing stake; $16.25 per share in stock, with Tempus option to pay up to 50% cash.
- Premium of 6% to Friday's close and 28% to 30-day VWAP; floating exchange ratio capped at 0.3356 Tempus shares per Personalis share.
- Closing expected late 2026 or early 2027, subject to Personalis shareholder approval, regulatory clearances, and customary conditions.
- Personalis reported Q2 preliminary revenue of $22.4M and 10,384 clinical tests, a 33% sequential increase in test volumes.
- Acquisition expands Tempus' reach in the $20B MRD market, combining Personalis' NeXT Personal test with Tempus' AI platform.

## SEC filing metadata
- accession: 0001193125-26-308469
- form_type: 8-K
- ticker: TEM
- cik: 0001717115
- company_name: Tempus AI, Inc.
- filed_at: 2026-07-20T13:03:42+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1717115/000119312526308469/0001193125-26-308469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1717115/000119312526308469/d124162d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-308469
- JSON: https://secwatch.observer/filing/0001193125-26-308469.json
- Plain text: https://secwatch.observer/filing/0001193125-26-308469.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.